KindredBio Leadership

Richard Chin, MD

Richard Chin, MD

Founder and Chief Executive Officer

Richard Chin is a Harvard-trained physician and a former Rhodes Scholar with a track record of almost a dozen drug approvals and over 50 INDs. Drugs Richard developed, including Lucentis®, Xolair®, Tysabri®, and Rituxan® for immune diseases, have current aggregate sales of well over $10 billion per year.

Previously, Richard was Head of Clinical Research for the Biotherapeutics Unit at Genentech where he oversaw all of Genentech’s drug development programs except oncology products; Senior VP of Global Development at Elan; CEO of Oxigene, a NASDAQ-listed biotechnology company; and CEO of OneWorld Health, a Gates Foundation-funded nonprofit developing drugs for impoverished patients in developing countries. Richard was named by BusinessWeek in 2006 as one of 99 youngest public company CEOs in the United States. He has authored several major textbooks on clinical development and teaches drug development at UCSF.

Denise Bevers

Denise Bevers

Founder and Chief Operating Officer

Denise Bevers is an expert in clinical operations, medical affairs, and scientific communications. Denise has over 20 years of pharmaceutical and research experience, and has managed dozens of products and development programs from Phase I through Phase IV. She was previously at Elan Pharmaceuticals, Scripps Clinic and Research Foundation, Quintiles, and SkyePharma. Most recently, she was President and Founding Partner of SD Scientific, a full-service medical affairs and communications company.

Stephen Sundlof, DVM, PhD

Stephen Sundlof, DVM, PhD

Chief Scientific Officer and Executive Vice President of Regulatory Affairs and Quality

Steve Sundlof served as the Director of the Center for Veterinary Medicine at the FDA from 1994 to 2008 where he oversaw all veterinary products regulated by the FDA. He also served as the Director of Center for Food Safety and Applied Nutrition at the FDA from 2008 to 2010. Steve began his career in 1980 on the faculty of the University of Florida’s College of Veterinary Medicine. In 1994, FDA Commissioner David Kessler named him the CVM director.

Wendy Wee

Wendy Wee

Vice President of Finance

Wendy Wee is a financial executive with over 30 years of public company experience in both the biotechnology and high-technology industries. From 2002 to 2014, Wendy served in various positions at Telik a biotechnology company focused on oncology, including Vice President of Finance, Principal Financial and Accounting Officer, and Controller. Prior to Telik, she was the Senior Director of Finance and Controller at Connetics, Inc., a biotechnology company focused on dermatological diseases. Previous to that she held various management positions at Silicon Graphics, Inc., MIPS Computer Systems and Unisys Corporation.

Hangjun Zhan, PhD

Hangjun Zhan, PhD

Vice President, Biologics Research

Dr. Zhan is a highly regarded protein biochemist and biophysicist with 20 years of drug discovery experience in the biotechnology industry. He joined KindredBio in February 2014 to lead our biologics research. Most recently, Dr. Zhan served as an Executive Member at Aragen Biosciences and led their protein sciences group. Prior to that, Dr. Zhan established and led the Protein Biochemistry Group at Exelixis, including Protein Expression, Fermentation/Bioproduction, Protein Purification/Biophysics, and Proteomics. His team’s work led to more than 20 drug candidates. Prior to that, Dr. Zhan was Group Leader of Protein Chemistry at Axys Biopharmaceuticals (Celera), where he managed a fermentation group and a protein biochemistry group. Dr. Zhan completed his post-doctoral training in Dr. John Collier’s lab at Harvard Medical School, where he applied in-depth biophysics to elucidate dynamic protein structural changes in solution and in membrane. He received his Ph.D. from the University of Washington, where he discovered a novel chemical signaling molecule involved in bacterial invasion.

Jenna Hahn

Jenna Hahn

Director, Sales and Marketing

Specializing in the companion animal and equine industries, Jenna Hahn has over 15 years of sales, marketing, and product launch experience. Jenna has worked in the veterinary division of Hill’s Pet Nutrition and Merck and for animal health companies such as Merial and IDEXX. She has consulted for many small businesses in the pet and equine markets, helping to bring their products to the veterinary market and providing insight into the industry. She currently sits on the Board of Directors for the Northern California Association of Equine Practitioners. Jenna is very active in the veterinary community, where she has spent her career working directly with veterinarians and their staff to help improve the quality of life for the animals we love.

Melinda Poole O’Banion, DVM

Melinda Poole O’Banion, DVM

Senior Director of Clinical Development and Regulatory Affairs

Melinda Poole O’Banion is an equine internal medicine trained specialist. She trained in an ACVIM and ABVP residency program at Mississippi State University College of Veterinary Medicine where she also served as clinical teaching faculty for 2 years. Post academia, she transitioned into the animal health industry in clinical research and development working on novel drugs for dogs, cats and horses. Melinda was previously at Boehringer Ingelheim Vetmedica, Elanco Animal Health, and Dechra Veterinary Products. She was the key clinical development member for Prascend® (pergolide mesylate) for horses and Osphos® (clodronate injection) for horses. Melinda has 14 years of animal health industry experience developing drugs for animals; she has worked on numerous small molecules for dogs, cats and horses in early and late stage development.

Valentine S. Williams DVM, MS, DACVS

Valentine S. Williams DVM, MS, DACVS

Director of Veterinary Affairs

Valentine Williams is a board certified equine surgeon with extensive experience in academia, private equine practice and the animal health industry. She started her veterinary career serving in multi-disciplinary private equine practices with a heavy focus on sports medicine, lameness, and surgery prior to transitioning to an industry career. In private practice, she specialized in equine orthopedic and soft tissue surgery as well as equine reproduction, lameness, routine care, emergency care, internal medicine, and neonatal care. She has a broad and diverse animal health background serving Fort Dodge Animal Health and Ceva Animal Health in technical services, marketing and sales support, pre-approval drug development, post-approval life cycle management, pharmacovigilance, and regulatory. Her experience spans both the companion animal (dogs/cats and horses) and food animal (cattle) sector. Her diverse background in the animal pharmaceutical and biological industry is unique and allows her the opportunity to function in many roles serving the veterinarian. She has a passion for education and bringing science to the practice of veterinary medicine.